Consolidation and maintenance therapy with lenalidomide, bortezomib and dexamethasone (RVD) in high-risk myeloma patients

References

Page 1

	Year	Citations
International uniform response criteria for multiple myeloma Brian G.M. Durie, J-L Harousseau, Jesús F. San Miguel, Leukemia Hematological MalignancyOncologyMalignant Blood DisorderHematologyMultiple Myeloma	2006	2.6K
Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myelome Hervé Avet‐Loiseau, Michel Attal, Philippe Moreau, Blood	2007	899
Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma Paul G. Richardson, Edie Weller, Sagar Lonial, Blood	2010	855
Bortezomib Induction and Maintenance Treatment in Patients With Newly Diagnosed Multiple Myeloma: Results of the Randomized Phase III HOVON-65/ GMMG-HD4 Trial Pieter Sonneveld, Ingo Schmidt‐Wolf, Bronno van der Holt, Journal of Clinical Oncology	2012	819
Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications Nicholas Mitsiades, Constantine S. Mitsiades, Vassiliki Poulaki, Blood	2002	666
Bortezomib Plus Dexamethasone Is Superior to Vincristine Plus Doxorubicin Plus Dexamethasone As Induction Treatment Prior to Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: Results of the IFM 2005-01 Phase III Trial Jean‐Luc Harousseau, Michel Attal, Hervé Avet‐Loiseau, Journal of Clinical Oncology	2010	528
Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA/GEM study Laura Rosiñol, Albert Oriol, Ana Isabel Teruel, Blood	2012	485
Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma Shaji Kumar, Ian W. Flinn, Paul G. Richardson, Blood	2012	449
Bortezomib Plus Dexamethasone Induction Improves Outcome of Patients With t(4;14) Myeloma but Not Outcome of Patients With del(17p) Hervé Avet‐Loiseau, Xavier Leleu, Murielle Roussel, Journal of Clinical Oncology	2010	419
Administration of bortezomib before and after autologous stem cell transplantation improves outcome in multiple myeloma patients with deletion 17p Kai Neben, Henk M. Lokhorst, Anna Jauch, Blood	2011	353

Page 1